cystic fibrosis | mecfa 19/28

MECFA Blog

Mucus, cough and chronic lung disease: New discoveries

As a cold ends, a severe mucus cough starts. Sound familiar? Two studies now give explanations: First, crucial mechanisms of the mucus in...

AzurRx BioPharma Receives Sanction of Cystic Fibrosis Therapeutics Development Network for the Study

On track to initiate Phase 2 trial in cystic fibrosis patients in the fourth quarter of 2018 and conclude in 2019 NEW YORK, Nov. 01, 2018...

#NACFC2018 — Vertex Presents Latest Clinical Data on CFTR Modulators

Vertex Pharmaceuticals’ VX-659 or VX-445 in combination with Kalydeco(ivacaftor) and tezacaftor (VX-661) can improve the lung function of...

PTI-808 and PTI-801 Combo Improves Lung Function in CF Patients, Phase 1 Data Show

Treatment with a combo of Proteostasis Therapeutics’ investigational CFTR modulator therapies — PTI-808, a potentiator, plus PTI-801, a...

Proteostasis Therapeutics' Double and Triple-Combo CF Drugs Possible Threat to Vertex Dominance

Boston-based Proteostasis Therapeutics announced positive preliminary data from its ongoing Phase I clinical trial of PTI-808 and PTI-801...

Scientists Reveal New Cystic Fibrosis Treatments Work Best in Inflamed Airways

New UNC School of Medicine research led by Martina Gentzsch, PhD, and Carla Ribeiro, PhD, suggests that cystic fibrosis drugs used to...

Understanding antibiotic resistance in patients with cystic fibrosis

A defective gene causes thick, sticky mucus to build up in the lungs of patients with cystic fibrosis (CF). There, it traps bacteria,...

#NACFC — Sound Pharmaceuticals to Present Preliminary Data on Ototoxicity Study

Sound Pharmaceuticals (SPI) will present data on the incidence and severity of ototoxicity in cystic fibrosis (CF) patients who received...

Vertex and Treating CF: High Hopes for Triple Combinations and Gene Therapy Possibilities

Editor’s note: This is third in a four-part series looking at Vertex Pharmaceuticals and its “all in for CF” approach. Here, we look at...

Does Monotherapy With Correctors Have Clinical Benefit in Cystic Fibrosis?

Insufficient evidence exists to demonstrate that monotherapy with correctors has clinically important effects in individuals with cystic...

Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds

VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE

A case for improved carrier screening

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

The search for molecular glue in targeted disease control

Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says

Harvard is working with Boston hospitals to test existing cystic fibrosis drug to help coronavirus p